In collaboration with Merck Research Laboratories, we have demonstrated that conjugating Pfs25 with OMPC, the Outer Membrane Protein Complex of the Neisseria meningitides subgroup B, significantly increased immunogenicity and response longevity of Pfs25 in multiple animal models, including non human primates. The induced immune sera effectively blocked malaria transmission as evaluated in an ex-vivo membrane feeding assay. The collaborative efforts continues to evaluate conjugates using different carriers and adjuvants, in searching for a cost-effective process for vaccine product development.

Project Start
Project End
Budget Start
Budget End
Support Year
7
Fiscal Year
2013
Total Cost
$672,456
Indirect Cost
City
State
Country
Zip Code
Radtke, Andrea J; Anderson, Charles F; Riteau, Nicolas et al. (2017) Adjuvant and carrier protein-dependent T-cell priming promotes a robust antibody response against the Plasmodium falciparum Pfs25 vaccine candidate. Sci Rep 7:40312
Jones, David S; Rowe, Christopher G; Chen, Beth et al. (2016) A Method for Producing Protein Nanoparticles with Applications in Vaccines. PLoS One 11:e0138761
MacDonald, Nicholas J; Nguyen, Vu; Shimp, Richard et al. (2016) Structural and Immunological Characterization of Recombinant 6-Cysteine Domains of the Plasmodium falciparum Sexual Stage Protein Pfs230. J Biol Chem 291:19913-22
Wu, Yimin; Sinden, Robert E; Churcher, Thomas S et al. (2015) Development of malaria transmission-blocking vaccines: from concept to product. Adv Parasitol 89:109-52
Cheru, Lediya; Wu, Yimin; Diouf, Ababacar et al. (2010) The IC(50) of anti-Pfs25 antibody in membrane-feeding assay varies among species. Vaccine 28:4423-9
Kubler-Kielb, Joanna; Majadly, Fathy; Biesova, Zuzana et al. (2010) A bicomponent Plasmodium falciparum investigational vaccine composed of protein-peptide conjugates. Proc Natl Acad Sci U S A 107:1172-7